• Kymera Therapeutics’ third-quarter 2026 net loss widened 61% year over year to $132 million.
• Collaboration revenue fell to none, while research and development expenses jumped 73% year over year to $128.51 million.
• Cash, cash equivalents and marketable securities totaled $1.65 billion at September 30, 2026, providing expected runway into 2029.
• KT-579 showed positive Phase 1 healthy-volunteer results; a Phase 1b lupus trial is planned to start by early 2027.
• KT-621 Phase 2b atopic dermatitis topline data remain expected by year-end 2026, with the first Phase 3 trial anticipated by mid-2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kymera Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610290700PRIMZONEFULLFEED9855497) on October 29, 2026, and is solely responsible for the information contained therein.